IMVT Immunovant Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IMVT

Price (delayed)

$27.75

Market cap

$4.03B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.83

Enterprise value

$3.34B

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous ...

Highlights
The equity has soared by 170% from the previous quarter and by 64% YoY
IMVT's quick ratio has surged by 105% year-on-year
IMVT's net income is down by 23% YoY but it is up by 4.6% from the previous quarter
Immunovant's EPS has decreased by 10% YoY but it has increased by 7% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://immunovant.com
Peers: OMER OMGA

Key stats

What are the main financial stats of IMVT
Market
Shares outstanding
145.29M
Market cap
$4.03B
Enterprise value
$3.34B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.91
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$244.11M
EBITDA
-$242.72M
Free cash flow
-$210.56M
Per share
EPS
-$1.83
Free cash flow per share
-$1.46
Book value per share
$4.7
Revenue per share
$0
TBVPS
$4.92
Balance sheet
Total assets
$711.45M
Total liabilities
$32.1M
Debt
$306,000
Equity
$679.34M
Working capital
$678.67M
Liquidity
Debt to equity
0
Current ratio
22.14
Quick ratio
21.56
Net debt/EBITDA
2.85
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-55.3%
Return on equity
-61.1%
Return on invested capital
N/A
Return on capital employed
-35.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMVT stock price

How has the Immunovant stock price performed over time
Intraday
-3.65%
1 week
-2.01%
1 month
-11.11%
1 year
71.61%
YTD
-34.13%
QTD
-14.11%

Financial performance

How have Immunovant's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$266.09M
Net income
-$243.45M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 32% year-on-year
IMVT's net income is down by 23% YoY but it is up by 4.6% from the previous quarter

Growth

What is Immunovant's growth rate over time

Valuation

What is Immunovant stock price valuation
P/E
N/A
P/B
5.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Immunovant's EPS has decreased by 10% YoY but it has increased by 7% QoQ
The equity has soared by 170% from the previous quarter and by 64% YoY
The stock's price to book (P/B) is 45% less than its last 4 quarters average of 10.7 and 29% less than its 5-year quarterly average of 8.3

Efficiency

How efficient is Immunovant business performance
IMVT's return on equity is down by 32% year-on-year but it is up by 20% since the previous quarter
IMVT's return on assets is down by 29% year-on-year but it is up by 18% since the previous quarter

Dividends

What is IMVT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMVT.

Financial health

How did Immunovant financials performed over time
IMVT's total assets has soared by 144% QoQ and by 56% YoY
IMVT's quick ratio has surged by 105% year-on-year
Immunovant's debt is 100% lower than its equity
The equity has soared by 170% from the previous quarter and by 64% YoY
Immunovant's debt has shrunk by 80% YoY and by 50% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.